Anti-tumor activity of chemokine is affected by both kinds of tumors and the activation state of the host's immune system: Implications for chemokine-based cancer immunotherapy

Biochemical and Biophysical Research Communications

Volumn 317, Issue 1, 2004, Pages 68-76

  Okada, Naoki ^a   Gao, Jian Qing ^b,c   Sasaki, Akinori ^a   Niwa, Masakazu ^a   Okada, Yuka ^d   Nakayama, Takashi ^e   Yoshie, Osamu ^e   Mizuguchi, Hiroyuki ^f   Hayakawa, Takao ^f   Fujita, Takuya ^a   Yamamoto, Akira ^a   Tsutsumi, Yasuo ^b   Mayumi, Tadanori ^b   Nakagawa, Shinsaku ^b  

^a KYOTO PHARMACEUTICAL UNIVERSITY   (Japan)

^b OSAKA UNIVERSITY   (Japan)

^c ZHEJIANG UNIVERSITY   (China)

^d MUKOGAWA WOMEN'S UNIVERSITY   (Japan)

^e KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f NATIONAL INSTITUTE OF HEALTH SCIENCES   (Japan)

Author keywords

Adenovirus vector; Anti tumor activity; Chemokine; Gene immunotherapy; Transfection

Indexed keywords

ADENOVIRUS VECTOR; CHEMOKINE; CUTANEOUS T CELL ATTACKING CHEMOKINE; LYMPHOTACTIN; MACROPHAGE DERIVED CHEMOKINE; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 3BETA; MELANOMA ANTIGEN 1; NEUROTACTIN; SECONDARY LYMPHOID TISSUE CHEMOKINE; THYMUS AND ACTIVATION REGULATED CHEMOKINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CONTROLLED STUDY; EMBRYO; FEMALE; GENE THERAPY; GENETIC TRANSDUCTION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR GROWTH;

ADENOVIRIDAE; ANIMALS; CELL LINE, TUMOR; CHEMOKINES; CHEMOTAXIS; GENE EXPRESSION; GENE THERAPY; GENETIC VECTORS; HUMANS; IMMUNOTHERAPY; MEMBRANE GLYCOPROTEINS; MICE; NEOPLASM PROTEINS; NEOPLASMS; RECOMBINANT PROTEINS; RNA, MESSENGER; TRANSDUCTION, GENETIC; TRANSFECTION;

ADENOVIRIDAE; MURINAE;

EID: 12144291472     PISSN: 0006291X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbrc.2004.03.013     Document Type: Article

References (37)

1. Zlotnik A., Yoshie O. Chemokines: a new classification system and their role in immunity. Immunity. 12:2000;121-127.
2. Yoshie O., Imai T., Nomiyama H. Chemokines in immunity. Adv. Immunol. 78:2001;57-110.
3. Homey B., Muller A., Zlotnik A. Chemokines: agents for the immunotherapy of cancer? Nat. Rev. Immunol. 2:2002;175-184.
4. Sharma S., Stolina M., Luo J., Strieter R.M., Burdick M., Zhu L.X., Batra R.K., Dubinett S.M. Secondary lymphoid tissue chemokine mediates T cell-dependent antitumor responses in vivo. J. Immunol. 164:2000;4558-4563.
5. Fushimi T., Kojima A., Moore M.A., Crystal R.G. Macrophage inflammatory protein 3α transgene attracts dendritic cells to established murine tumors and suppresses tumor growth. J. Clin. Invest. 105:2000;1383-1393.
6. Braun S.E., Chen K., Foster R.G., Kim C.H., Hromas R., Kaplan M.H., Broxmeyer H.E., Cornetta K. The CC chemokine CKβ-11/MIP-3β/ELC/Exodus 3 mediates tumor rejection of murine breast cancer cells through NK cells. J. Immunol. 164:2000;4025-4031.
7. Miyata T., Yamamoto S., Sakamoto K., Morishita R., Kaneda Y. Novel immunotherapy for peritoneal dissemination of murine colon cancer with macrophage inflammatory protein-1β mediated by a tumor-specific vector, HVJ cationic liposomes. Cancer Gene Ther. 8:2001;852-860.
8. Guo J., Zhang M., Wang B., Yuan Z., Guo Z., Chen T., Yu Y., Qin Z., Cao X. Fractalkine transgene induces T-cell-dependent antitumor immunity through chemoattraction and activation of dendritic cells. Int. J. Cancer. 103:2003;212-220.
9. Kozarsky K.F., Wilson J.M. Gene therapy: adenovirus vectors. Curr. Opin. Genet. Dev. 3:1993;499-503.
10. Kay M.A., Woo S.L. Gene therapy for metabolic disorders. Trends Genet. 19:1994;253-257.
11. Mizuguchi H., Koizumi N., Hosono T., Utoguchi N., Watanabe Y., Kay M.A., Hayakawa T. A simplified system for constructing recombinant adenoviral vectors containing heterologous peptides in the HI loop of their fiber knob. Gene Ther. 8:2001;730-735.
12. Koizumi N., Mizuguchi H., Hosono T., Ishii-Watabe A., Uchida E., Utoguchi N., Watanabe Y., Hayakawa T. Efficient gene transfer by fiber-mutant adenoviral vectors containing RGD peptide. Biochim. Biophys. Acta. 1568:2001;13-20.
13. Okada Y., Okada N., Nakagawa S., Mizuguchi H., Takahashi K., Mizuno N., Fujita T., Yamamoto A., Hayakawa T., Mayumi T. Tumor necrosis factor α-gene therapy for an established murine melanoma using RGD (Arg-Gly-Asp) fiber-mutant adenovirus vectors. Jpn. J. Cancer Res. 93:2002;436-444.
14. Nomiyama H., Hieshima K., Nakayama T., Sakaguchi T., Fujisawa R., Tanase S., Nishiura H., Matsuno K., Takamori H., Tabira Y., Yamamoto T., Miura R., Yoshie O. Human CC chemokine liver-expressed chemokine/CCL16 is a functional ligand for CCR1, CCR2 and CCR5, and constitutively expressed by hepatocytes. Int. Immunol. 13:2001;1021-1029.
15. Mizuguchi H., Kay M.A. Efficient construction of a recombinant adenovirus vector by an improved in vitro ligation method. Hum. Gene Ther. 9:1998;2577-2583.
16. Mizuguchi H., Kay M.A. A simple method for constructing E1- and E1/E4-deleted recombinant adenoviral vectors. Hum. Gene Ther. 10:1999;2013-2017.
17. Okada N., Tsukada Y., Nakagawa S., Mizuguchi H., Mori K., Saito T., Fujita T., Yamamoto A., Hayakawa T., Mayumi T. Efficient gene delivery into dendritic cells by fiber-mutant adenovirus vectors. Biochem. Biophys. Res. Commun. 282:2001;173-179.
18. Okada N., Masunaga Y., Okada Y., Iiyama S., Mori N., Tsuda T., Matsubara A., Mizuguchi H., Hayakawa T., Fujita T., Yamamoto A. Gene transduction efficiency and maturation status in mouse bone marrow-derived dendritic cells infected with conventional or RGD fiber-mutant adenovirus vectors. Cancer Gene Ther. 10:2003;421-431.
19. Gao J.Q., Tsuda Y., Katayama K., Nakayama T., Hatanaka Y., Tani Y., Mizuguchi H., Hayakawa T., Yoshie O., Tsutsumi Y., Mayumi T., Nakagawa S. Antitumor effect by interleukin-11 receptor α-locus chemokine/CCL27, introduced into tumor cells through a recombinant adenovirus vector. Cancer Res. 63:2003;4420-4425.
20. Janik P., Briand P., Hartmann N.R. The effect of estrone-progesterone treatment on cell proliferation kinetics of hormone-dependent GR mouse mammary tumours. Cancer Res. 35:1975;3698-3704.
21. Okada N., Masunaga Y., Okada Y., Mizuguchi H., Iiyama S., Mori N., Sasaki A., Nakagawa S., Mayumi T., Hayakawa T., Fujita T., Yamamoto A. Dendritic cells transduced with gp100 gene by RGD fiber-mutant adenovirus vectors are highly efficacious in generating anti-B16BL6 melanoma immunity in mice. Gene Ther. 10:2003;1891-1902.
22. Paillard F. Cytokine and chemokine: a stimulating couple. Hum. Gene Ther. 10:1999;695-696.
23. Laning J., Kawasaki H., Tanaka E., Luo Y., Dorf M.E. Inhibition of in vivo tumor growth by the β chemokine, TCA3. J. Immunol. 153:1994;4625-4635.
24. Hirose K., Hakozaki M., Nyunoya Y., Kobayashi Y., Matsushita K., Takenouchi T., Mikata A., Mukaida N., Matsushima K. Chemokine gene transfection into tumour cells reduced tumorigenicity in nude mice in association with neutrophilic infiltration. Br. J. Cancer. 72:1995;708-714.
25. Mule J.J., Custer M., Averbook B., Yang J.C., Weber J.S., Goeddel D.V., Rosenberg S.A., Schall T.J. RANTES secretion by gene-modified tumor cells results in loss of tumorigenicity in vivo: role of immune cell subpopulations. Hum. Gene Ther. 7:1996;1545-1553.
26. Nakashima E., Oya A., Kubota Y., Kanada N., Matsushita R., Takeda K., Ichimura F., Kuno K., Mukaida N., Hirose K., Nakanishi I., Ujiie T., Matsushima K. A candidate for cancer gene therapy: MIP-1α gene transfer to an adenocarcinoma cell line reduced tumorigenicity and induced protective immunity in immunocompetent mice. Pharm. Res. 13:1996;1896-1901.
27. Maric M., Liu Y. Strong cytotoxic T lymphocyte responses to a macrophage inflammatory protein 1α-expressing tumor: linkage between inflammation and specific immunity. Cancer Res. 59:1999;5549-5553.
28. Guo J., Wang B., Zhang M., Chen T., Yu Y., Regulier E., Homann H.E., Qin Z., Ju D.W., Cao X. Macrophage-derived chemokine gene transfer results in tumor regression in murine lung carcinoma model through efficient induction of antitumor immunity. Gene Ther. 9:2002;793-803.
29. Emtage P.C., Wan Y., Hitt M., Graham F.L., Muller W.J., Zlotnik A., Gauldie J. Adenoviral vectors expressing lymphotactin and interleukin 2 or lymphotactin and interleukin 12 synergize to facilitate tumor regression in murine breast cancer models. Hum. Gene Ther. 10:1999;697-709.
30. Narvaiza I., Mazzolini G., Barajas M., Duarte M., Zaratiegui M., Qian C., Melero I., Prieto J. Intratumoral coinjection of two adenoviruses, one encoding the chemokine IFN-γ-inducible protein-10 and another encoding IL-12, results in marked antitumoral synergy. J. Immunol. 164:2000;3112-3122.
31. Ruehlmann J.M., Xiang R., Niethammer A.G., Ba Y., Pertl U., Dolman C.S., Gillies S.D., Reisfeld R.A. MIG (CXCL9) chemokine gene therapy combines with antibody-cytokine fusion protein to suppress growth and dissemination of murine colon carcinoma. Cancer Res. 61:2001;8498-8503.
32. Tolba K.A., Bowers W.J., Muller J., Housekneckt V., Giuliano R.E., Federoff H.J., Rosenblatt J.D. Herpes simplex virus (HSV) amplicon-mediated codelivery of secondary lymphoid tissue chemokine and CD40L results in augmented antitumor activity. Cancer Res. 62:2002;6545-6551.
33. Steinman R.M. Dendritic cells and immune-based therapies. Exp. Hematol. 24:1996;859-862.
34. Banchereau J., Steinman R.M. Dendritic cells and the control of immunity. Nature. 392:1998;245-252.
35. Granucci F., Zanoni I., Feau S., Ricciardi-Castagnoli P. Dendritic cell regulation of immune responses: a new role for interleukin 2 at the intersection of innate and adaptive immunity. EMBO J. 22:2003;2546-2551.
36. Fong L., Engleman E.G. Dendritic cells in cancer immunotherapy. Annu. Rev. Immunol. 18:2000;245-273.
37. Volin M.V., Woods J.M., Amin M.A., Connors M.A., Harlow L.A., Koch A.E. Fractalkine: a novel angiogenic chemokine in rheumatoid arthritis. Am. J. Pathol. 159:2001;1521-1530.